Fig. 5: Efficacy of (+)-CBD-oct in normalizing aberrant dendritic arborization, spine density, and morphology in a mouse model of developmental epilepsy.
From: Carvone derived cannabidiol enantiomers as novel anticonvulsants
a Timeline of developmental administration (red lines) of 20 mg*kg-1 ( + )-CBD-oct p.o. or vehicle control; schematic of dendritic spine morphology and classification. b–e Representative cortical pyramidal cells impregnated with Golgi-Cox stain. bi–ei Dendritic spine segments (10 µm in length). f Sholl analysis of dendritic arbor in pyramidal cells (Wildtype vehicle: 10.631 ± 0.485; Gabra2-1 vehicle: 7.369 ± 0.485; Wildtype (+)-CBD-oct: 10.446 ± 0.485; Gabra2-1 ( + )-CBD-oct: 10.677 ± 0.485). g Total spine density per 10 µm (Wildtype vehicle: 5.651 ± 0.159; Gabra2-1 vehicle: 10.941 ± 0.242; Wildtype (+)-CBD-oct: 7.652 ± 0.125; Gabra2-1 ( + )-CBD-oct: 8.559 ± 0.203). h Quantification of immature filopodia (Wildtype vehicle: 1.440 ± 0.217; Gabra2-1 vehicle: 5.320 ± 0.263; Wildtype (+)-CBD-oct: 2.240 ± 0.226; Gabra2-1 ( + )-CBD-oct: 2.720 ± 0.255). i Quantification of mature dendritic spines (Wildtype vehicle: 1.520 ± 0.165; Gabra2-1 vehicle: 2.320 ± 0.256; Wildtype (+)-CBD-oct: 3.320 ± 0.281; Gabra2-1 ( + )-CBD-oct: 3.760 ± 0.393). All values listed are mean ± standard error, p values from Two Way Repeated Measures ANOVA, or Two Way ANOVA with Bonferroni post hoc; or t-test. Line graphs are plotted as mean and standard error, and box plots are plotted as median, first and third quartile, and range.
